This is a defining moment in Robeauté’s journey to revolutionize brain disease therapies.
A moment that opens a major door to a widely promising future.
What an honor and a pleasure it is for me, together with Joana Cartocci to be announcing Robeauté’s Series A, a substantial 27 M€ with top investors, providing both funds and support.
This significant amount raised in Series A in a difficult period for financial market speaks volume to the boldness of our investors as well as the achievement of Robeauté's team.
However, this Series A, above all, is providing Robeauté with the means and the reach to perform our first clinical trials in patients, as well as consolidate our position in the US -our initial market. And this is the door that is now opened to Robeauté!
I would like to thank our new investors for trusting and joining us on our mission to revolutionize brain disease therapies with our microrobot: Plural, Cherry Ventures, Kindred Ventures who lead the round as well as LocalGlobe, Think.Health and Brainlab !
Ian Hogarth, Carina N., Filip Felician Dames, Katharina Baratta-Dragono, Julia Hawkins, Steve Jang, Kanyi Maqubela, Frank Heppner, Stefan Vilsmeier, Josef Bartl, Schmidt Robert
Each coming with game-changing means and superpowers !
Our next major milestone will take place in the brain !
